Breast Cancer Moon Shot Update
MOON SHOTS PROGRAM
Help end breast cancer
Every year in the U.S., approximately 235,000 men and women are
diagnosed with breast
cancer and more than 40,000 succumb to it. Nearly 69,000 patients
have the subtype known as triple-negative breast cancer (TNBC), which
causes almost 12,000 deaths annually. The Breast Cancer Moon
Shot? is determined to defeat this deadly type of breast
Finding the right target
A flood of new knowledge and technology makes now the time to fast-track the cancer fight and make a giant leap for patients. We're merging today’s high potential for achievement with our unique knowledge and expertise, derived from decades of leadership in the cancer field.
Most successful treatments for breast cancer take aim at specific proteins expressed by individual tumors: estrogen receptor, progesterone receptor or human epidermal growth factor receptor 2 (HER2). But TNBC doesn’t express any of these biomarkers, so there’s no current option for targeted therapy. This limits treatment mainly to surgery and chemotherapy, which are less effective against TNBC. Even if caught early, TNBC has an overall five-year survival of 60% compared to 80% for other types. To improve patient outcomes, we’re researching novel genetic markers to identify new plans of attack.
STORIES OF HOPE
Triple negative breast cancer survivor benefits from immunotherapy trial
Lori was diagnosed with triple-negative breast cancer at age 38, after finding a lump in her right breast. She didn’t know much about clinical trials when she first came to MD Anderson in May 2017. When conventional treatment methods weren't effective, Lori followed her doctor's advice to participate in an immunotherapy clinical trial led by MD Anderson’s Breast Cancer Moon Shot? team. She sees value in the prospect of helping other women through her clinical trial participation.
A better way to treat chemo-resistant TNBC
In the era of targeted therapy, the inefficiency of treating triple-negative breast cancer (TNBC) can be particularly frustrating. Chemotherapy works for half of patients, but they can’t be identified in advance, and other promising drugs seemed to have little effect in general clinical trials.
The Breast Cancer Moon Shot has launched a clinical trial platform to personalize treatment for the aggressive breast cancer that’s best known for what it doesn’t have – three targets for precision medicine that have helped extend survival of other breast cancer patients. By analyzing biopsies, they’re guiding patients to clinical trials of drugs most likely to hit their tumor’s target.
An important mission
The Breast Cancer Moon Shot is leading several new and exciting projects that can quickly make a difference in the detection and treatment of breast cancer.